Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04509700 · ClinicalTrials.gov registry record · Phase 2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
A Phase 2 study of B-cell Malignancies, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT04509700 is a Phase 2 study of B-cell Malignancies that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 112 participants, below the 316-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04509700, a Phase 2 study of B-cell Malignancies, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
Conditions Studied
Interventions
- DRUG Parsaclisib
- DRUG parsaclisib + itacitinib
- DRUG parsaclisib + ruxolitinib
- DRUG parsaclisib + ibrutinib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- California Cancer Associates For Research and Excellence - Fresno
- Innovative Clinical Research Institute - Long Beach
Alabama
- Uab Comprehensive Cancer Center - Birmingham
- University of Alabama At Birmingham - Birmingham
Arizona
- Mayo Clinic Rochester - Phoenix
- University of Arizona Cancer Center-Out Pt. - Tucson
Missouri
- Saint Luke'S Hospital of Kansas City - Kansas City
- Hca Midwest Health-Research Medical Center - Kansas City
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Rocky Mountain Cancer Center - Aurora
Illinois
- Rush University Medical Center-Consultants in Hematology - Chicago
Kansas
- University of Kansas Hospital Authority - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04509700
The ClinicalTrials.gov registry entry for NCT04509700 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 316-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (65% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Malignancies appearing as the primary indexed condition, and to 4 interventions - of which Parsaclisib is the first listed.
NCT04509700 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04509700 about?
NCT04509700 is a clinical study titled "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)". This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
What is the current status of trial NCT04509700?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2020-08-03. Estimated completion is 2027-09-30.
What conditions does trial NCT04509700 study?
This clinical trial studies the following conditions: B-cell Malignancies.
What interventions are being tested in trial NCT04509700?
The interventions under investigation include: Parsaclisib (DRUG), parsaclisib + itacitinib (DRUG), parsaclisib + ruxolitinib (DRUG), parsaclisib + ibrutinib (DRUG).
Who is sponsoring clinical trial NCT04509700?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04509700 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
-
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.